A RNA Research and Manufacturing facility opened today within the Macquarie University Innovation Precinct, says the NSW government.
According to US website medlineplus.gov, ‘RNA (ribonucleic acid) is a vital nucleic acid found in all living cells, acting as a single-stranded messenger that translates DNA instructions into proteins. It is essential for protein synthesis, gene regulation, and acts as the genetic material for many viruses. Medical applications include mRNA vaccines, disease testing, and therapeutic research’
In a media release, the NSW government said, ‘NSW is set to become a global leader’ with the technology in RNA Research and Manufacturing with the Minns Labor Government opening a new $96 million facility today within the Macquarie University Innovation Precinct’.
‘Construction of the RNA Facility has been completed on time marking a new era in the state’s ability to translate, develop and manufacture life-saving RNA therapeutics.
‘This RNA Facility will place NSW in a strong position in the fight against current and emerging diseases by bolstering domestic RNA manufacturing capability, attracting investment, creating local jobs and fostering collaboration between universities, research institutes and industry.
‘The COVID‑19 pandemic underscored the urgent need for Australia to have local capability to rapidly develop and manufacture vaccines and therapeutics. With global supply chains stretched and international supply limited, the new RNA Facility ensures NSW is better prepared for future pandemics by enabling the fast production of RNA vaccines and treatments when they are needed most.
‘Located within the Macquarie University Innovation Precinct, the RNA Facility includes advanced laboratories and support spaces that will make it the only site in Australia capable of producing a wide range of new and existing RNA therapeutics under one roof. Industry partner and operator Aurora Biosynthetics will now engage with researchers and clients who aim to advance their therapeutic innovations from the laboratory towards clinical trials.
‘In addition to vaccines, the applications of RNA technology are diverse, ranging from treatments for cancers and rare genetic diseases to pest‑control solutions for agricultural use.
‘The NSW Government plans to provide an additional $119 million over 10 years in support of RNA R&D projects at the RNA Facility, and in July last year, launched the $17.6 million NSW RNA Research and Training Network along with the $6 million RNA Pipeline Grants Program.
‘The project was delivered by Health Infrastructure in collaboration with the Office of the Chief Scientist & Engineer. RNA Australia led by Chair Kate Pounder and Chief Executive Officer Paul McDonald will provide ongoing engagement with the Australian academic community along with Aurora Biosynthesis. Ownership of the Facility will now transfer to Property & Development NSW’, the media release added.
For four decades The Echo has printed the stories some people loved, some people hated, and some pretended not to read. If you want us to keep telling the truth, the real truth, not the sugar-coated version. We’ll need your support to keep the presses rolling. 
